Susceptibility patterns and cross-resistance of antibiotics against Pseudomonas aeruginosa isolated from burn patients in the South of Iran

Burns : Journal of the International Society for Burn Injuries
Aziz JaponiShohreh Farshad

Abstract

Pseudomonas aeruginosa plays a prominent role in serious infections in burn patients. Rapid acquisition of multi-drug resistance leads to high morbidity and mortality, especially in burn centers. Ten antibiotics, which were widely used in our burn patients were selected. MICs for imipenem, mropenem, cefepime, ceftazidime, cafoparazone/sulbactam, ticarcillin/clavulanate, piperacillin/tazobactam, ciprofloxacin, tobramycin and amikacin to 70 strains of P. aeruginosa, which were isolated from burn patients were determined by the E-test method (AB Biodisk, Sweden). Extended-spectrum beta-lactamase, group I inducible beta-lactamases and metallo-beta-lactamase activities were also determined. Imipenem and meropenum were the most active in vitro antibacterial agents followed by ciprofloxacin (p<0.05), whereas, ticarcillin/clavulanate was the least active. Almost all (98-100%) of the resistant isolates also showed cross-resistance to cefepime. The majority of imipenem and meropenem resistant isolates (85-100% and 76-100%) demonstrated cross-resistance to all the other antibiotics. ESBLs were detected in only three (4.3%) isolates, whereas, inducible beta-lactamase was observed in eight (11.4%) isolates. Metallo-beta-lactamase was detect...Continue Reading

References

Aug 1, 1992·Burns : Journal of the International Society for Burn Injuries·G D TaylorE Tredget
Dec 1, 1992·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·E E TredgetJ F Burke
Mar 1, 1994·The Journal of Burn Care & Rehabilitation·H A ShankowskyE E Tredget
Dec 24, 1997·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·N TroilletY Carmeli
Aug 26, 1998·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·R E Hancock
Nov 17, 1999·Molecular Microbiology·M L Vasil, U A Ochsner
Feb 27, 2001·The Journal of Antimicrobial Chemotherapy·D M Livermore
Jun 23, 2001·The Journal of Antimicrobial Chemotherapy·A P MacGowan, R Wise
Aug 30, 2001·Burns : Journal of the International Society for Burn Injuries·M E InnesR C Cartotto
Feb 2, 2002·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·David M Livermore

❮ Previous
Next ❯

Citations

Oct 9, 2009·Surgical Infections·Ludwik K BranskiDavid N Herndon
Nov 29, 2012·Indian Journal of Critical Care Medicine : Peer-reviewed, Official Publication of Indian Society of Critical Care Medicine·V KumarS Kumari
Dec 18, 2013·Burns : Journal of the International Society for Burn Injuries·Amjed Fekih HassenMayssa Daiki
Mar 13, 2015·Iranian Red Crescent Medical Journal·Nastaran Fazeli, Hassan Momtaz
Feb 18, 2016·Infection, Genetics and Evolution : Journal of Molecular Epidemiology and Evolutionary Genetics in Infectious Diseases·Uri ObolskiLilach Hadany
Oct 23, 2010·Burns : Journal of the International Society for Burn Injuries·Patrick MaharJason Wasiak
Jun 16, 2009·Burns : Journal of the International Society for Burn Injuries·Akbar MirsalehianNarges Kalantari
Jun 9, 2009·Burns : Journal of the International Society for Burn Injuries·Farhat UllahJawad Ahmed
Sep 29, 2007·Diagnostic Microbiology and Infectious Disease·Azar D Khosravi, Fatemeh Mihani
Dec 4, 2014·Burns : Journal of the International Society for Burn Injuries·Manju PanghalJ P Yadav
Oct 16, 2016·American Journal of Infection Control·David van DuinSamuel W Jones
Oct 1, 2020·Journal of Chemotherapy·Marko M FolicSlobodan M Jankovic

❮ Previous
Next ❯

Related Concepts

Related Feeds

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Carbapenems

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Beta-lactamase Inhibitors (ASM)

Beta-lactamase inhibitors are a class of antibiotics that inhibit beta-lactamases, a family of enzymes involved in bacterial resistance to beta-lactam antibiotics. Here is the latest research.

Beta-lactamase Inhibitors

Beta-lactamase inhibitors are a class of antibiotics that inhibit beta-lactamases, a family of enzymes involved in bacterial resistance to beta-lactam antibiotics. Here is the latest research.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Carbapenems (ASM)

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Related Papers

Burns : Journal of the International Society for Burn Injuries
N AgnihotriR M Joshi
Burns : Journal of the International Society for Burn Injuries
Edward E TredgetSarvesh Logsetty
The Journal of Antimicrobial Chemotherapy
J D CavalloGroupe d'Etude de la Résistance de Pseudomonas aeruginosa aux Bêtalactamines
© 2021 Meta ULC. All rights reserved